ABOUT THE ACADEMY

Two audiences: doctors who use exosmart™, and the partners who distribute it. Written, produced and paid for by Global Regenerative Group, the company behind exosmart™.

It is not accredited CME or CPD. No outside body has reviewed it, and the certificates are training records rather than qualifications. What follows is how the modules are built, who checks them, and where the evidence runs out.

The usual product training is marketing with a certificate attached. It explains what a device does. It rarely explains what the evidence actually shows, and it almost never explains where that evidence runs out.

We built this the other way round. Every claim in a module traces to a named source. The strength of the evidence is on the page, so you can see at a glance whether you are looking at something measured in this device, something measured in a device made the same way, or something from the wider platelet-rich plasma literature. Trials that found no benefit are taught with the same weight as the ones that did. Where there is no study, the module says there is no study.

This is not caution for its own sake. A doctor who knows precisely where the evidence ends can hold a treatment decision under questioning from a patient, a colleague or a regulator.

Normal text.exosmart™ is a CE-marked Class IIa medical device: a singleuse cartridge that concentrates a patient's own plasma at the point of care by pushing it along the inside of hollow fibres whose walls hold back anything above roughly 15 kilodaltons.

Blood is drawn and spun on site. Both parts of the plasma go into the device together, the platelet-rich and the platelet-poor — around 30 mL from a 60 mL draw — and pass through 870 fibres. Water and small molecules leave through the fibre walls. Extracellular vesicles, platelets, growth factors, other signalling molecules and the larger plasma proteins stay in. About 6 mL comes out.

There is no isolation step, no purification step and no fractionation step, and that is deliberate. A filter designed to isolate vesicles alone would use a size limit in the hundreds of kilodaltons and would let the proteins wash away. This one keeps them, so the vesicles, the growth factors and the plasma proteins arrive together, the way they travel in blood. That is why we describe the output as the complete autologous plasma secretome rather than as platelet-rich plasma or as isolated vesicles.

The concentration step takes three to five minutes; with the draw and the spin the full workflow is on the order of ten to twenty minutes. The preparation is autologous throughout, and no chemical activator is added.

They govern every module in this Academy. They exist because we are not a neutral party,
and you should not have to take our word for anything. 

ABOUT THE ACADEMY

Two audiences: doctors who use exosmart™, and the partners who distribute it. Written, produced and paid for by Global Regenerative Group, the company behind exosmart™.

It is not accredited CME or CPD. No outside body has reviewed it, and the certificates are training records rather than qualifications. What follows is how the modules are built, who checks them, and where the evidence runs out.

The usual product training is marketing with a certificate attached. It explains what a device does. It rarely explains what the evidence actually shows, and it almost never explains where that evidence runs out.

We built this the other way round. Every claim in a module traces to a named source. The strength of the evidence is on the page, so you can see at a glance whether you are looking at something measured in this device, something measured in a device made the same way, or something from the wider platelet-rich plasma literature. Trials that found no benefit are taught with the same weight as the ones that did. Where there is no study, the module says there is no study.

This is not caution for its own sake. A doctor who knows precisely where the evidence ends can hold a treatment decision under questioning from a patient, a colleague or a regulator.

Normal text.exosmart™ is a CE-marked Class IIa medical device: a singleuse cartridge that concentrates a patient's own plasma at the point of care by pushing it along the inside of hollow fibres whose walls hold back anything above roughly 15 kilodaltons.

Blood is drawn and spun on site. Both parts of the plasma go into the device together, the platelet-rich and the platelet-poor — around 30 mL from a 60 mL draw — and pass through 870 fibres. Water and small molecules leave through the fibre walls. Extracellular vesicles, platelets, growth factors, other signalling molecules and the larger plasma proteins stay in. About 6 mL comes out.

There is no isolation step, no purification step and no fractionation step, and that is deliberate. A filter designed to isolate vesicles alone would use a size limit in the hundreds of kilodaltons and would let the proteins wash away. This one keeps them, so the vesicles, the growth factors and the plasma proteins arrive together, the way they travel in blood. That is why we describe the output as the complete autologous plasma secretome rather than as platelet-rich plasma or as isolated vesicles.

The concentration step takes three to five minutes; with the draw and the spin the full workflow is on the order of ten to twenty minutes. The preparation is autologous throughout, and no chemical activator is added.